VRTX ファイナンス： Vertex Pharmaceuticals Inc AI分析



財務状況

VRTX 財務

Vertex Pharmaceuticals Inc

$515.55

1.93%

$9.79

終値： Aug 17, 16:00:00 GMT-4

$513.96

-0.3%

$-1.58

アフターマーケット：Aug 17, 17:49:28 GMT-4

概要予測収入配当財務状況

主要データ

前終値

$505.75

始値

$508

当日レンジ

$502.53 - $517.76

52週レンジ

$362.5 - $533.67

取引高

1.0M

平均取引高

1.4M

配当利回り

1株当たり利益(TTM)

17.19

時価総額

$130.4B

VRTXとは何ですか？

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

特徴

Markets

News

利用規約プライバシーポリシー

Breakdown	TTM	06/30/2026	03/31/2026	12/31/2025	09/30/2025	06/30/2025
収入	12,587	3,333	2,986	3,190	3,076	2,964
収益成長率（YoY）	10%	12%	8%	10%	11%	12%
収益のコスト	1,762	489	392	466	414	407
売上総利益	10,824	2,844	2,594	2,724	2,661	2,557
販売、一般および管理	2,008	582	493	487	445	424
研究開発	3,906	993	961	973	977	978
運営費用	5,914	1,576	1,455	1,461	1,420	1,403
その他の非営業収入（費用）	23	32	0	0	-8	6
税引前利益	5,274	1,391	1,252	1,331	1,298	1,283
所得税費	869	292	221	139	215	250
純利益	4,405	1,099	1,031	1,191	1,082	1,032
純利益成長率	21%	6%	60%	30%	4%	-129%
流通済み株式数（希薄化後）	255.2	255.2	256.3	256.2	257.6	258.9
株式変動（前年比）	-1%	-1%	-1%	0%	-1%	0%
EPS（希薄化）	17.26	4.3	4.02	4.65	4.2	3.99
EPS成長率	23%	8%	61%	31%	5%	-129%
フリーキャッシュフロー	3,796	1,013	1,294	348	1,139	927
1株当たりフリーキャッシュフロー	--	--	--	--	--	--
粗利益	85.99%	85.32%	86.87%	85.39%	86.5%	86.26%
営業利益率	39%	38.04%	38.11%	39.56%	40.31%	38.9%
利益率	34.99%	32.97%	34.52%	37.33%	35.17%	34.81%
フリーキャッシュフロー利益率	30.15%	30.39%	43.33%	10.9%	37.02%	31.27%
EBITDA	5,132	1,324	1,193	1,317	1,294	1,204
EBITDAマージン	40.77%	39.72%	39.95%	41.28%	42.06%	40.62%
D&A による EBITDA	222	56	55	55	54	51
営業利益	4,910	1,268	1,138	1,262	1,240	1,153
営業利益率	39%	38.04%	38.11%	39.56%	40.31%	38.9%
実効税率	16.47%	20.99%	17.65%	10.44%	16.56%	19.48%

Breakdown

TTM

06/30/2026

03/31/2026

12/31/2025

09/30/2025

06/30/2025

収入

12,587

3,333

2,986

3,190

3,076

2,964

収益成長率（YoY）

10%

12%

10%

11%

12%

収益のコスト

1,762

489

392

466

414

407

売上総利益

10,824

2,844

2,594

2,724

2,661

2,557

販売、一般および管理

2,008

582

493

487

445

424

研究開発

3,906

993

961

973

977

978

運営費用

5,914

1,576

1,455

1,461

1,420

1,403

その他の非営業収入（費用）

-8

税引前利益

5,274

1,391

1,252

1,331

1,298

1,283

所得税費

869

292

221

139

215

250

純利益

4,405

1,099

1,031

1,191

1,082

1,032

純利益成長率

21%

60%

30%

-129%

流通済み株式数（希薄化後）

255.2

256.3

256.2

257.6

258.9

株式変動（前年比）

-1%

EPS（希薄化）

17.26

4.3

4.02

4.65

4.2

3.99

EPS成長率

23%

61%

31%

-129%

フリーキャッシュフロー

3,796

1,013

1,294

348

1,139

927

1株当たりフリーキャッシュフロー

粗利益

85.99%

85.32%

86.87%

85.39%

86.5%

86.26%

営業利益率

39%

38.04%

38.11%

39.56%

40.31%

38.9%

利益率

34.99%

32.97%

34.52%

37.33%

35.17%

34.81%

フリーキャッシュフロー利益率

30.15%

30.39%

43.33%

10.9%

37.02%

31.27%

EBITDA

5,132

1,324

1,193

1,317

1,294

1,204

EBITDAマージン

40.77%

39.72%

39.95%

41.28%

42.06%

40.62%

D&A による EBITDA

222

営業利益

4,910

1,268

1,138

1,262

1,240

1,153

営業利益率

39%

38.04%

38.11%

39.56%

40.31%

38.9%

実効税率

16.47%

20.99%

17.65%

10.44%

16.56%

19.48%

Follow-Up Questions

Báo cáo tài chính chính của Vertex Pharmaceuticals Inc là gì?



Theo báo cáo tài chính mới nhất (Form-10K), Vertex Pharmaceuticals Inc có tổng tài sản là $0, lợi nhuận ròng 損失 là $0

Tỷ lệ tài chính chính của VRTX là gì?



Tỷ lệ thanh khoản của Vertex Pharmaceuticals Inc là 0, tỷ suất lợi nhuận ròng là 0, doanh thu trên mỗi cổ phiếu là $0.

Doanh thu của Vertex Pharmaceuticals Inc được phân bổ theo phân khúc hoặc khu vực địa lý như thế nào?



Vertex Pharmaceuticals Inc の最大収益セグメントは Other で、最新の利益発表における収益は 644,700,000 です。地域別に見ると、Other Collaborative and Royalty が Vertex Pharmaceuticals Inc の主要市場であり、収益は 30,700,000 です。

Vertex Pharmaceuticals Inc có lợi nhuận không?



いいえ, theo báo cáo tài chính mới nhất, Vertex Pharmaceuticals Inc có lợi nhuận ròng 損失 là $0

Vertex Pharmaceuticals Inc có nợ không?



いいえ, Vertex Pharmaceuticals Inc có nợ là 0

Vertex Pharmaceuticals Inc có bao nhiêu cổ phiếu đang lưu hành?



Vertex Pharmaceuticals Inc có tổng cộng 0 cổ phiếu đang lưu hành

Vertex Pharmaceuticals Inc (VRTX) 財務

VRTX 株価推移チャート

主要データ

前終値

始値

当日レンジ

52週レンジ

取引高

平均取引高

配当利回り

1株当たり利益(TTM)

時価総額

VRTXとは何ですか？

Vertex Pharmaceuticals Inc (VRTX) 財務

VRTX 株価推移チャート

主要データ

前終値

始値

当日レンジ

52週レンジ

取引高

平均取引高

配当利回り

1株当たり利益(TTM)

時価総額

VRTXとは何ですか？

VRTX 収入

Follow-Up Questions

Báo cáo tài chính chính của Vertex Pharmaceuticals Inc là gì?

Tỷ lệ tài chính chính của VRTX là gì?

Doanh thu của Vertex Pharmaceuticals Inc được phân bổ theo phân khúc hoặc khu vực địa lý như thế nào?

Vertex Pharmaceuticals Inc có lợi nhuận không?

Vertex Pharmaceuticals Inc có nợ không?

Vertex Pharmaceuticals Inc có bao nhiêu cổ phiếu đang lưu hành?